Opportunities in Indian API Market
India, being the third largest API market in the Asia-Pacific region, has been gaining a lot of attention worldwide since the last few years. The accelerated growth of the Indian API market can be attributed to the increased efforts being made by the Indian government to improve the infrastructure of the API industry and provide maximum support to domestic API manufacturers. This is being done, so that India does not have to depend on other countries for the import of APIs. Indian API manufacturers are also trying to strengthen their hold of the regulated markets by various means. A major competitor for India in this field is China, which provides APIs at very low rates. However, all the hard work being put in by the API manufacturers and government will help India to become the top API market not only in Asia-Pacific, but also in the world.
In the report “Opportunities in Indian API Market”, RNCOS analysts have addressed the current scenario of the Indian API market, major drivers of the market, and factors hindering the growth of the market. Apart from this, the segmentation of the market by various parameters, such as type of manufacture, type of drug, type of API and type of therapeutic area, has also been specified. The important mergers and acquisitions in the Indian API market have also been mentioned in the report. Various initiatives taken by the government to promote the Indian API industry have been listed down. Owing to the various government initiatives, such as the declaration of 2015 as the “Year of APIs”, “Make in India” campaign, etc., the Indian API market is likely to show a promising growth in the coming years. The Indian API market is forecasted to grow at a CAGR of 13% from 2014-2020.
The report also mentions the key players in the Indian API Market. For every player, a brief business overview, geographic revenue break up, and segment wise revenue break up has been provided. A strength and weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of major players. A separate section has been provided in the report for the opportunities and recommendations for the development of the Indian API market. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Indian API market.
In the report “Opportunities in Indian API Market”, RNCOS analysts have addressed the current scenario of the Indian API market, major drivers of the market, and factors hindering the growth of the market. Apart from this, the segmentation of the market by various parameters, such as type of manufacture, type of drug, type of API and type of therapeutic area, has also been specified. The important mergers and acquisitions in the Indian API market have also been mentioned in the report. Various initiatives taken by the government to promote the Indian API industry have been listed down. Owing to the various government initiatives, such as the declaration of 2015 as the “Year of APIs”, “Make in India” campaign, etc., the Indian API market is likely to show a promising growth in the coming years. The Indian API market is forecasted to grow at a CAGR of 13% from 2014-2020.
The report also mentions the key players in the Indian API Market. For every player, a brief business overview, geographic revenue break up, and segment wise revenue break up has been provided. A strength and weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of major players. A separate section has been provided in the report for the opportunities and recommendations for the development of the Indian API market. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Indian API market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. INDIA API INDUSTRY OUTLOOK
3.1 Top 5 API Markets of the World
3.2 Share of India in Global API Market
3.3 Indian API Market Size (2009-2014)
3.4 Top 10 APIs in the Indian API Market
4. DRIVERS & CHALLENGES
4.1 Drivers
4.1.1 Rising Healthcare Expenditure
4.1.2 Increasing Disposable Incomes
4.1.3 Rise in Geriatric Population
4.1.4 Increasing Incidences of Chronic Diseases
4.1.5 Patent Expiry of Blockbuster Drugs
4.1.6 Increased Consumption of Generic Drugs
4.1.7 Invention of New Generation of APIs
4.2 Challenges
4.2.1 Overdependence on China for Imports
4.2.2 Complex License Renewal Procedure
4.2.3 Few Manufacturers in the API Industry
4.2.4 Inadequate Infrastructure Facilities
4.2.5 Lack of Government Support
4.2.6 Stringent Regulatory Policies
5. MARKET SEGMENTATION
5.1 By Type of Manufacturing
5.2 By Type of Drug
5.3 By Type of API
5.4 By Type of Therapeutic Area
6. MERGERS AND ACQUISITIONS
7. GOVERNMENT INITIATIVES
7.1 Katoch Committee
7.2 ‘Make in India’ Campaign
7.3 Pharma Vision 2020
7.4 Establishment of New NIPERs
8. REGULATORY SCENARIO
9. COMPETITIVE LANDSCAPE
9.1 Profiles
9.1.1 Sun Pharma
9.1.2 Cipla Limited
9.1.3 Biocon
9.1.4 Dr. Reddy’s Laboratories
9.1.5 Lupin Ltd.
9.1.6 Aurobindo Pharma Limited
9.1.7 Wockhardt
9.1.8 Zydus Cadila
9.1.9 Glenmark
9.1.10 Jubilant LifeSciences
10. FUTURE OUTLOOK
11. OPPORTUNITIES AND RECOMMENDATIONS
LIST OF TABLE:
Figure 3-1: India API Market Trade (%), 2009-2014
Figure 3-2: Top 5 API Markets of the World (%), 2014
Figure 3-3: Share of India in Global API Market (%), 2014
Figure 3-4: India API Market (Billion US$), 2009-2014
Figure 4-1: Healthcare Expenditure (% of GDP), 2009-2014
Figure 4-2: Personal Disposable Income (Billion US$), 2009-2014
Figure 4-3: Population Above 65 years (Million), 2009-2014
Figure 4-4: Diabetes Population in the Age Group 20-79 years (Million), 2013 & 2030
Figure 4-5: Number of Cancer Cases (‘000), 2014 & 2020
Figure 5-1: Share of Captive and Merchant Market APIs in Indian API Market (%), 2014
Figure 5-2: Share of Branded and Generic Drug APIs in Indian API Market (%), 2014
Figure 5-3: Share of Chemical/Small Molecule and Biotech APIs in Indian API Market (%), 2014
Figure 5-4: Share of APIs by their Application in Therapeutic Areas in Indian API Market (%), 2014
Figure 8-1: API License Procedure
Figure 9-1: Sun Pharma- Break up of Revenue by Therapeutic Segment (%), 2014
Figure 9-2: Sun Pharma- Break up of Revenue by Geography (%), 2014
Figure 9-3: Cipla Limited-Break up of Revenue by Geography (%), 2014
Figure 9-4: Biocon-Break up of Revenue by Geography (%), 2014
Figure 9-5: Dr. Reddy's Laboratories - Break up of Revenue by Geography (%), 2014
Figure 9-6: Lupin Limited- Revenues by Trade (Billion US$), 2014
Figure 9-7: Aurobindo Pharma Limited - Break up of Revenue of Formulations by Geography (%), 2014
Figure 9-8: Wockhardt- Break up of Revenue by Geography (%), 2014
Figure 9-9: Zydus Cadila- Break up of Revenue by Geography (%), 2014
Figure 9-10: Glenmark- Break up of Revenue by Geography (%), 2014
Figure 9-11: Jubilant LifeSciences- Break up of Revenue by Geography (%), 2014
Figure 10-1: Indian API Market (Billion US$), 2015-2020
LIST OF TABLE:
Table 3-1: Top 10 APIs in the Indian API Market (2014)
Table 4-1: List of Blockbuster Drugs Losing Patent (2015-2020)
Table 4-2: API Import from China (2011-2015)
Table 6 1: Mergers and Acquisitions in Indian Pharma Industry (2014-2015)
Table 9-1: Sun Pharma- Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-2: Biocon-Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-3: Dr. Reddy's Laboratories - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-4: Lupin Limited- Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-5: Aurobindo Pharma Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-6: Wockhardt- Revenue by Business Segment (Billion US$), 2013 & 2014
Table 9-7: Zydus Cadila- Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-8: Glenmark- Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-9: Jubilant LifeSciences- Revenues by Business Segment (Billion US$), 2013 & 2014
2. RESEARCH METHODOLOGY
3. INDIA API INDUSTRY OUTLOOK
3.1 Top 5 API Markets of the World
3.2 Share of India in Global API Market
3.3 Indian API Market Size (2009-2014)
3.4 Top 10 APIs in the Indian API Market
4. DRIVERS & CHALLENGES
4.1 Drivers
4.1.1 Rising Healthcare Expenditure
4.1.2 Increasing Disposable Incomes
4.1.3 Rise in Geriatric Population
4.1.4 Increasing Incidences of Chronic Diseases
4.1.5 Patent Expiry of Blockbuster Drugs
4.1.6 Increased Consumption of Generic Drugs
4.1.7 Invention of New Generation of APIs
4.2 Challenges
4.2.1 Overdependence on China for Imports
4.2.2 Complex License Renewal Procedure
4.2.3 Few Manufacturers in the API Industry
4.2.4 Inadequate Infrastructure Facilities
4.2.5 Lack of Government Support
4.2.6 Stringent Regulatory Policies
5. MARKET SEGMENTATION
5.1 By Type of Manufacturing
5.2 By Type of Drug
5.3 By Type of API
5.4 By Type of Therapeutic Area
6. MERGERS AND ACQUISITIONS
7. GOVERNMENT INITIATIVES
7.1 Katoch Committee
7.2 ‘Make in India’ Campaign
7.3 Pharma Vision 2020
7.4 Establishment of New NIPERs
8. REGULATORY SCENARIO
9. COMPETITIVE LANDSCAPE
9.1 Profiles
9.1.1 Sun Pharma
9.1.2 Cipla Limited
9.1.3 Biocon
9.1.4 Dr. Reddy’s Laboratories
9.1.5 Lupin Ltd.
9.1.6 Aurobindo Pharma Limited
9.1.7 Wockhardt
9.1.8 Zydus Cadila
9.1.9 Glenmark
9.1.10 Jubilant LifeSciences
10. FUTURE OUTLOOK
11. OPPORTUNITIES AND RECOMMENDATIONS
LIST OF TABLE:
Figure 3-1: India API Market Trade (%), 2009-2014
Figure 3-2: Top 5 API Markets of the World (%), 2014
Figure 3-3: Share of India in Global API Market (%), 2014
Figure 3-4: India API Market (Billion US$), 2009-2014
Figure 4-1: Healthcare Expenditure (% of GDP), 2009-2014
Figure 4-2: Personal Disposable Income (Billion US$), 2009-2014
Figure 4-3: Population Above 65 years (Million), 2009-2014
Figure 4-4: Diabetes Population in the Age Group 20-79 years (Million), 2013 & 2030
Figure 4-5: Number of Cancer Cases (‘000), 2014 & 2020
Figure 5-1: Share of Captive and Merchant Market APIs in Indian API Market (%), 2014
Figure 5-2: Share of Branded and Generic Drug APIs in Indian API Market (%), 2014
Figure 5-3: Share of Chemical/Small Molecule and Biotech APIs in Indian API Market (%), 2014
Figure 5-4: Share of APIs by their Application in Therapeutic Areas in Indian API Market (%), 2014
Figure 8-1: API License Procedure
Figure 9-1: Sun Pharma- Break up of Revenue by Therapeutic Segment (%), 2014
Figure 9-2: Sun Pharma- Break up of Revenue by Geography (%), 2014
Figure 9-3: Cipla Limited-Break up of Revenue by Geography (%), 2014
Figure 9-4: Biocon-Break up of Revenue by Geography (%), 2014
Figure 9-5: Dr. Reddy's Laboratories - Break up of Revenue by Geography (%), 2014
Figure 9-6: Lupin Limited- Revenues by Trade (Billion US$), 2014
Figure 9-7: Aurobindo Pharma Limited - Break up of Revenue of Formulations by Geography (%), 2014
Figure 9-8: Wockhardt- Break up of Revenue by Geography (%), 2014
Figure 9-9: Zydus Cadila- Break up of Revenue by Geography (%), 2014
Figure 9-10: Glenmark- Break up of Revenue by Geography (%), 2014
Figure 9-11: Jubilant LifeSciences- Break up of Revenue by Geography (%), 2014
Figure 10-1: Indian API Market (Billion US$), 2015-2020
LIST OF TABLE:
Table 3-1: Top 10 APIs in the Indian API Market (2014)
Table 4-1: List of Blockbuster Drugs Losing Patent (2015-2020)
Table 4-2: API Import from China (2011-2015)
Table 6 1: Mergers and Acquisitions in Indian Pharma Industry (2014-2015)
Table 9-1: Sun Pharma- Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-2: Biocon-Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-3: Dr. Reddy's Laboratories - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-4: Lupin Limited- Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-5: Aurobindo Pharma Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-6: Wockhardt- Revenue by Business Segment (Billion US$), 2013 & 2014
Table 9-7: Zydus Cadila- Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-8: Glenmark- Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-9: Jubilant LifeSciences- Revenues by Business Segment (Billion US$), 2013 & 2014
